ethyl 3-{4-chloro-3-[(1,3,4-trimethyl-1H-pyrazol-5-yl)oxy]phenyl}propionate | 1043915-35-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 3-{4-chloro-3-[(1,3,4-trimethyl-1H-pyrazol-5-yl)oxy]phenyl}propionate
• 英文别名: Ethyl 3-[4-chloro-3-(2,4,5-trimethylpyrazol-3-yl)oxyphenyl]propanoate
• CAS: 1043915-35-0
• 化学式: C₁₇H₂₁ClN₂O₃
• 分子量: 336.818
• InChiKey: RRGPQZXOVNMRIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  53.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• PYRAZOLE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2128138A1

  公开（公告）日：2009-12-02

  The present invention aims to provide an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. The present invention relates to an agent for the prophylaxis or treatment of diabetes comprising a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof.

  本发明旨在提供一种用于预防或治疗糖尿病的药物，具有优越的降血糖作用，并且与较少的副作用，如体重增加等相关。本发明涉及一种用于预防或治疗糖尿病的药物，包括由以下式表示的化合物：其中每个符号如描述中所定义，或其盐，或其前药。
• Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes
  申请人：Johnstone Craig

  公开号：US20090253676A1

  公开（公告）日：2009-10-08

  Compounds of Formula (I): wherein: R 1 is hydroxymethyl; R 2 is selected from —C(O)NR 4 R 5 , —SO 2 NR 4 R 5 , —S(O) p R 4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R 3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R 4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R 5 is hydrogen or (1-4C)alkyl; or R 4 and R 5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

  化学式（I）的化合物：其中：R1为羟甲基；R2选自- C（O）NR4R5，-SO2NR4R5，-S（O）pR4和HET-2; HET-1为5-或6-成员的，可选择性取代C-连接的杂芳基环；HET-2为4-，5-或6-成员的，C-或N-连接的可选择性取代杂环烷基环；R3选自卤素，氟甲基，二氟甲基，三氟甲基，甲基，甲氧基和氰基；R4选自例如氢，可选择性取代的（1-4C）烷基和HET-2；R5为氢或（1-4C）烷基；或R4和R5与它们所附着的氮原子一起可以形成由HET-3定义的杂环烷基环系统；HET-3例如为可选择性取代的N-连接，4、5或6成员的，饱和或部分不饱和的杂环烷基环；p为（每次独立）0、1或2；m为0或1；n为0、1或2；但当m为0时，则n为1或2；或其盐、前药或溶剂。还描述了它们作为GLK激活剂的用途、含有它们的制药组合物以及它们的制备方法。
• US6271383B1
  申请人：——

  公开号：US6271383B1

  公开（公告）日：2001-08-07
• US6458793B1
  申请人：——

  公开号：US6458793B1

  公开（公告）日：2002-10-01
• US7737136B2
  申请人：——

  公开号：US7737136B2

  公开（公告）日：2010-06-15